Editorial Policy: Facts, Sources and the No-Medical-Advice Line
Released · Last reviewed · how we verify
TopGLP1Providers reports what GLP-1 telehealth programs charge and how they are structured, from each program’s own pages and with the date each figure was read. Our computed ranking scores every program on two of the seven v4.1 categories, from each program’s own pages; our featured pick is an editorial selection shown separately, every page is medically reviewed, and we never give medical advice.
Facts over adjectives. Claims about programs are sourced to what the program itself publishes, with a read date. Where we characterize a program (a watch-out, “starting price”, “not re-read”), the evidence is stated in the same place. We do not publish anonymous review sentiment, star ratings or testimonials.
No medical advice. We report prices and program terms. Whether any GLP-1, brand or compounded, is appropriate for a given person is a licensed clinician’s call. Compounded tirzepatide and semaglutide are not FDA-approved; we describe them as made with the drug in Zepbound or Wegovy, not the same product.
Ranking and money. NexLife is our featured pick, an editorial selection shown apart from the computed ranking, which scores every compounded program on pricing transparency and total annual cost (see the rankings). TopGLP1Providers is affiliate-supported, as the footer of every page states. Earlier versions of this page said our rankings were mechanical and that no commercial consideration could affect them; those statements were withdrawn on November 10, 2026 and logged in corrections.
Medical review. Pages are researched by Dr. Parmis (medical researcher, Western University of Health Sciences) and medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC). Each page shows when it was last medically reviewed.
Errors are logged. When we get a figure wrong, the correction is published at /corrections/ with the wrong value, the right value and the dates.